Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 12/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.46 |
| ▸ | PDE4A | P27815 | 11/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8007015 | 0.85 | PDE4D (0.47) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL4404449 | 0.82 | PDE4A (0.53) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL15623863 | 0.82 | PDE4B (0.39) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL12923596 | 0.80 | PDE4D (0.48) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL8006958 | 0.77 | PDE4D (0.50) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL1027909 | 0.75 | PDE4D (0.74) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL14458154 | 0.75 | PDE4B (0.60) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL15763184 | 0.75 | PDE4B (0.60) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL15790497 | 0.72 | PDE4B (0.59) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL15790650 | 0.72 | PDE4B (0.55) | PDE4DPDE4BPDE4APDE4CABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2464651-B1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2016-04-20 | — | — | EP | disclosed |
| US-8933073-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2015-01-13 | — | — | US | disclosed |
| US-8933073-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2015-01-13 | — | — | US | disclosed |
| US-8865662-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-8865662-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20140142100-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140142100-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2014-05-22 | — | — | US | disclosed |
| EP-2247294-B1 | MACROLIDES FOR TREATING DISEASES MEDIATED THROUGH PDE INHIBITION | BASILEA PHARMACEUTICA AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| US-8410065-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-8410065-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-20120277174-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2012-11-01 | — | — | US | disclosed |
| US-20120277174-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2012-11-01 | — | — | US | disclosed |
| US-20110053876-A1 | MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-03-03 | — | — | US | disclosed |
| US-20110053876-A1 | MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-03-03 | — | — | US | disclosed |
| WO-2011018510-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-02-17 | — | — | WO | disclosed |
| WO-2009106419-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009098320-A2 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277174-A1 | NEW MACROLIDES AND THEIR USE | PDE4A, PDE4B, PDE12 | PDE4D 5/4885PDE4B 2/4885PDE4A 1/4885 |
| US-20110053876-A1 | MACROLIDES AND THEIR USE | PDE4A, PDE12, PDE4B | PDE4D 6/4885PDE4B 3/4885PDE4A 1/4885 |
| US-20140142100-A1 | NEW MACROLIDES AND THEIR USE | PDE4A, PDE4B, PDE12 | PDE4D 5/4885PDE4B 2/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.